MX2013006858A - Compuesto triciclicos inhibidores de la pi3k y metodos de uso. - Google Patents
Compuesto triciclicos inhibidores de la pi3k y metodos de uso.Info
- Publication number
- MX2013006858A MX2013006858A MX2013006858A MX2013006858A MX2013006858A MX 2013006858 A MX2013006858 A MX 2013006858A MX 2013006858 A MX2013006858 A MX 2013006858A MX 2013006858 A MX2013006858 A MX 2013006858A MX 2013006858 A MX2013006858 A MX 2013006858A
- Authority
- MX
- Mexico
- Prior art keywords
- pi3k inhibitor
- inhibitor compounds
- formula
- methods
- tricyclic pi3k
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Virology (AREA)
Abstract
Se describen compuestos tricíclicos inhibidores de la PI3k de la fórmula 1 con actividad anticancerosa, actividad antiinflamatoria y propiedades inmunorreguladoras y, más específicamente, con actividad moduladora o inhibidora de la quinasa PI3. Se describen método para utilizar los compuestos tricíclicos inhibidores de la PI3k de la fórmula 1 para el diagnóstico o el tratamiento "in vitro", "in situ" e "in vivo" de células de mamíferos, de organismos o de estados patológicos asociados (Ver Formula) Los compuestos de la fórmula 1 incluyen a los estereoisómeros, los isómeros geométricos, los tautómeros y las sales farmacéuticamente aceptables de los mismos. Las líneas dis15 continuas indican un doble enlace opcional, pero por lo menos una línea discontinua es un doble enlace. Los sustituyentes tienen los significados aquí definidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42369410P | 2010-12-16 | 2010-12-16 | |
PCT/US2011/065101 WO2012082997A1 (en) | 2010-12-16 | 2011-12-15 | Tricyclic pi3k inhibitor compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013006858A true MX2013006858A (es) | 2013-07-29 |
Family
ID=45478511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013006858A MX2013006858A (es) | 2010-12-16 | 2011-12-15 | Compuesto triciclicos inhibidores de la pi3k y metodos de uso. |
Country Status (32)
Country | Link |
---|---|
US (5) | US8883799B2 (es) |
EP (3) | EP3053925A1 (es) |
JP (1) | JP5775171B2 (es) |
KR (2) | KR20140099556A (es) |
CN (2) | CN103313989B (es) |
AR (2) | AR084312A1 (es) |
AU (1) | AU2011343712B2 (es) |
BR (1) | BR112013014914B8 (es) |
CA (1) | CA2820078C (es) |
CL (1) | CL2013001093A1 (es) |
CO (1) | CO6710942A2 (es) |
CR (1) | CR20130247A (es) |
DK (1) | DK2651951T3 (es) |
EA (1) | EA026134B1 (es) |
EC (1) | ECSP13012692A (es) |
ES (1) | ES2530545T3 (es) |
HK (1) | HK1185871A1 (es) |
HR (1) | HRP20150127T1 (es) |
IL (1) | IL225778A (es) |
MX (1) | MX2013006858A (es) |
MY (1) | MY164910A (es) |
NZ (1) | NZ609448A (es) |
PE (1) | PE20140314A1 (es) |
PL (1) | PL2651951T3 (es) |
PT (1) | PT2651951E (es) |
RS (1) | RS53768B1 (es) |
SG (2) | SG10201510347QA (es) |
SI (1) | SI2651951T1 (es) |
TW (2) | TWI441824B (es) |
UA (1) | UA109688C2 (es) |
WO (1) | WO2012082997A1 (es) |
ZA (1) | ZA201304128B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2879497C (en) * | 2012-08-30 | 2017-08-01 | F. Hoffmann-La Roche Ag | Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use |
US9676765B2 (en) | 2012-11-07 | 2017-06-13 | Karus Therapeutics Limited | Histone deacetylase inhibitors and their use in therapy |
AR095443A1 (es) * | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
WO2014181137A1 (en) | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
TW201520215A (zh) * | 2013-05-13 | 2015-06-01 | Daiichi Sankyo Co Ltd | N-□啉基嘌呤衍生物之製造方法 |
CN104557955B (zh) * | 2013-10-23 | 2017-05-03 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的三环类化合物,其制备方法和用途 |
SG11201605097SA (en) * | 2013-12-24 | 2016-07-28 | Bristol Myers Squibb Co | Tricyclic compounds as anticancer agents |
EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
PT3233852T (pt) * | 2014-12-18 | 2020-09-10 | Hoffmann La Roche | Tetrahidro-pirido[3,4-b]indóis como moduladores do recetor de estrogénio e suas utilizações |
JP6038111B2 (ja) * | 2014-12-27 | 2016-12-07 | ヤマサ醤油株式会社 | 多置換7−デアザプリン誘導体合成のための2,6−ジクロロ−8−ヨード−7−デアザプリン |
US9758529B2 (en) * | 2015-02-11 | 2017-09-12 | Sunovion Pharmaceuticals Inc. | Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders |
WO2016142310A1 (en) * | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Tricyclic dlk inhibitors and uses thereof |
KR20170131444A (ko) | 2015-03-30 | 2017-11-29 | 다이이찌 산쿄 가부시키가이샤 | 6-모르폴리닐-2-피라졸릴-9h-푸린 유도체 및 pi3k 저해제로서의 이들의 용도 |
WO2017004133A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
GB201514751D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
WO2017090058A1 (en) * | 2015-11-23 | 2017-06-01 | Council Of Scientific & Industrial Research | Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof |
EP3978500B1 (en) * | 2015-12-16 | 2023-11-22 | Genentech, Inc. | Process for the preparation of tricyclic pi3k inhibitor compounds |
US10570149B2 (en) * | 2016-05-24 | 2020-02-25 | Merck Patent Gmbh | Tricyclic heterocylic derivatives |
EP3858835A1 (en) | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
CN106008528A (zh) * | 2016-07-28 | 2016-10-12 | 安徽赛迪生物科技有限公司 | 一种合成4-氯-5,7-二氢-6h-吡咯并[2,3-d]嘧啶-6-酮的方法 |
US10196403B2 (en) | 2016-07-29 | 2019-02-05 | Sunovion Pharmaceuticals Inc. | Compounds and compositions and uses thereof |
BR112019001407A2 (pt) | 2016-07-29 | 2019-07-09 | Pgi Drug Discovery Llc | compostos e composições e usos dos mesmos |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
EP3521290A4 (en) | 2016-09-29 | 2020-04-22 | Daiichi Sankyo Company, Limited | CRYSTALS OF [2- (1-METHYL-1H-PYRAZOL-4-YL) -6- (MORPHOLIN-4-YL) -9H-PURIN-8-YL] [4- (MORPHOLIN-4-YL) PIPERIDIN-1 -YL] METHANONE AND PHARMACEUTICAL SAFE SALT THEREOF |
CN110300590A (zh) * | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
ES2911522T3 (es) | 2016-12-02 | 2022-05-19 | Daiichi Sankyo Co Ltd | Novedosa endo-ß-n-acetilglucosaminidasa |
JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
EP3847176A1 (en) | 2018-09-07 | 2021-07-14 | Otsuka Pharmaceutical Co., Ltd. | Heterocyclic compound |
CN112839933A (zh) | 2018-10-02 | 2021-05-25 | 先正达参股股份有限公司 | 杀有害生物活性苯-酰胺和吖嗪-酰胺化合物 |
CN109134480A (zh) * | 2018-10-19 | 2019-01-04 | 辽宁大学 | 一种新型4-苯氨基苯并呋喃并[2,3-d]嘧啶类化合物及其应用 |
JP2022525169A (ja) | 2019-03-14 | 2022-05-11 | サノビオン ファーマシューティカルズ インク | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 |
TW202102489A (zh) | 2019-03-29 | 2021-01-16 | 瑞士商先正達農作物保護公司 | 殺有害生物活性之二𠯤-醯胺化合物 |
JP2022527548A (ja) | 2019-04-05 | 2022-06-02 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に活性なジアジン-アミド化合物 |
EP3953343A1 (en) | 2019-04-11 | 2022-02-16 | Syngenta Crop Protection AG | Pesticidally active diazine-amide compounds |
US20220289715A1 (en) | 2019-08-23 | 2022-09-15 | Syngenta Crop Protection Ag | Pesticidally active pyrazine-amide compounds |
GB201913921D0 (en) * | 2019-09-26 | 2019-11-13 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CN113004303A (zh) * | 2019-12-18 | 2021-06-22 | 江苏恒瑞医药股份有限公司 | 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用 |
MX2022014573A (es) | 2020-05-19 | 2022-12-15 | G1 Therapeutics Inc | Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos. |
EP4352050A1 (en) | 2021-06-09 | 2024-04-17 | Syngenta Crop Protection AG | Pesticidally active diazine-amide compounds |
WO2023072849A1 (en) | 2021-10-27 | 2023-05-04 | Syngenta Crop Protection Ag | Pesticidally active pyridazinone compounds |
WO2023104714A1 (en) | 2021-12-10 | 2023-06-15 | Syngenta Crop Protection Ag | Pesticidally active pyridazinone compounds |
KR20230115493A (ko) | 2022-01-27 | 2023-08-03 | 인제대학교 산학협력단 | 특이적 PI3K p110δ 억제제를 유효성분으로 함유하는 스타스민1 관련 질환 예방 또는 치료용 조성물 |
CN115413669B (zh) * | 2022-06-14 | 2024-03-15 | 湖南大学 | 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用 |
CN115403593B (zh) * | 2022-09-22 | 2024-02-02 | 河南师范大学 | 一种环加成合成手性嘌呤[3,2-c]并噁唑化合物的方法 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3016378A (en) | 1959-07-01 | 1962-01-09 | Thomae Gmbh Dr K | Amino-substituted purine derivatives |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
JPS4872196U (es) | 1971-12-11 | 1973-09-10 | ||
JPS4872196A (es) * | 1971-12-27 | 1973-09-29 | ||
GB1570494A (en) | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
US4510144A (en) * | 1981-08-26 | 1985-04-09 | Newport Pharmaceuticals International | Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives |
JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
DE3406533A1 (de) | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
JPS6216477A (ja) | 1985-07-15 | 1987-01-24 | Maruishi Seiyaku Kk | 抗ウイルス活性を有する2−(4−ピリジルアミノメチル)−ベンズイミダゾ−ル誘導体 |
US4740230A (en) | 1985-09-13 | 1988-04-26 | Idemitsu Kosan Company Limited | Triazine derivatives, and herbicides containing the derivatives as the effective component |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
CA1279648C (en) | 1986-07-11 | 1991-01-29 | Haruo Kuriyama | 2-(4-pyridylaminometyl)-benzimidazole derivatives having antiviral activity |
US4932998A (en) | 1986-09-30 | 1990-06-12 | Idemitsu Kosan Company Limited | Triazine derivatives, and herbicides comprising the same as the effective ingredient |
US5332744A (en) | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
JP3093112B2 (ja) | 1994-09-01 | 2000-10-03 | 新日本製鐵株式会社 | 塗覆装鋼製打ち込み部材 |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
EP1277738B1 (en) | 2000-04-27 | 2011-03-30 | Astellas Pharma Inc. | Condensed heteroaryl derivatives |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US8828902B2 (en) | 2001-07-12 | 2014-09-09 | Reaxa Limited | Microencapsulated catalyst methods of preparation and method of use thereof |
AU2002323475B2 (en) | 2001-09-13 | 2006-09-28 | Synta Pharmaceuticals Corp | 2-aroylimidazole compounds for treating cancer |
WO2003031406A2 (en) | 2001-10-12 | 2003-04-17 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
US6949644B2 (en) | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
WO2004035740A2 (en) | 2002-10-15 | 2004-04-29 | Synta Pharmaceuticals Corp. | Aromatic bicyclic heterocyles to modulate 1l - 12 production |
US20080058297A1 (en) | 2003-05-29 | 2008-03-06 | Synta Pharmaceuticals Corp. | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss |
AR045445A1 (es) | 2003-08-05 | 2005-10-26 | Vertex Pharma | Compuestos ihinibidores de canales ionicos regulados por voltaje |
US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
US7129244B2 (en) | 2003-09-18 | 2006-10-31 | Conforma Therapeutics Corporation | Triazolopyrimidines and related analogs as HSP90-inhibitors |
JP4800216B2 (ja) | 2003-10-24 | 2011-10-26 | エグゼリクシス, インコーポレイテッド | p70S6キナーゼモジュレーターおよび使用方法 |
US20050187389A1 (en) | 2004-01-13 | 2005-08-25 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
US20080096861A1 (en) | 2004-08-02 | 2008-04-24 | Smithkline Beecham Corporation | Chemical Compounds |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
US20080269239A1 (en) | 2004-11-11 | 2008-10-30 | Argenta Discovery Ltd. | Pyrimidine Compounds as Histamine Modulators |
BRPI0617165B1 (pt) | 2005-10-07 | 2023-10-03 | Exelixis Inc | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
ATE471940T1 (de) | 2006-04-26 | 2010-07-15 | Hoffmann La Roche | Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor |
AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
TW200801012A (en) | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
KR20090021155A (ko) | 2006-04-26 | 2009-02-27 | 에프. 호프만-라 로슈 아게 | Pi3k 억제제로서의 피리미딘 유도체 |
GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
RU2445312C2 (ru) | 2006-08-23 | 2012-03-20 | Кудос Фармасьютиклз Лимитед | ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR |
MX2009002927A (es) | 2006-09-15 | 2009-03-31 | Pfizer Prod Inc | Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3. |
WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
WO2008043031A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
EP2074128B1 (en) | 2006-10-16 | 2013-08-14 | Medicis Pharmaceutical Corporation | Therapeutic pyrazolyl thienopyridines |
BRPI0717907A2 (pt) | 2006-12-07 | 2013-11-05 | Genentech Inc | "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit" |
JP5284977B2 (ja) | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
CA2682019C (en) | 2007-03-28 | 2016-08-09 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
DE602008004650D1 (de) | 2007-04-12 | 2011-03-03 | Hoffmann La Roche | Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase |
WO2008152394A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
CN101679456B (zh) | 2007-06-12 | 2012-09-05 | 霍夫曼-拉罗奇有限公司 | 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用 |
WO2008152387A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Quinazoline derivatives as pi3 kinase inhibitors |
JP5492769B2 (ja) * | 2007-06-26 | 2014-05-14 | サノフイ | 縮環されたベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的金属触媒合成 |
WO2009034386A1 (en) | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
CN101932587A (zh) | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
CN101835779B (zh) | 2007-10-26 | 2014-01-29 | 霍夫曼-拉罗奇有限公司 | 作为pi3激酶抑制剂的嘌呤衍生物 |
GB0721095D0 (en) | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
GB0725218D0 (en) | 2007-12-24 | 2008-02-06 | Syngenta Ltd | Chemical compounds |
ES2494365T3 (es) | 2008-01-30 | 2014-09-15 | Genentech, Inc. | Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso |
KR20110042153A (ko) | 2008-05-30 | 2011-04-25 | 제넨테크, 인크. | 퓨린 pi3k 억제 화합물 및 사용 방법 |
CA2728183C (en) | 2008-06-20 | 2016-10-25 | Astrazeneca Ab | Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pryimidines |
RU2473549C2 (ru) | 2008-07-31 | 2013-01-27 | Дженентек, Инк. | Пиримидиновые соединения, композиции и способы применения |
EP2346334A1 (en) | 2008-09-26 | 2011-07-27 | Merck Sharp & Dohme Corp. | Oxazolobenzimidazole derivatives |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
US8653098B2 (en) | 2008-11-20 | 2014-02-18 | Genentech, Inc. | Pyrazolopyridine PI3K inhibitor compounds and methods of use |
EP2451811A1 (en) | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
CA2761445A1 (en) | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
CN102480961A (zh) | 2009-06-24 | 2012-05-30 | 健泰科生物技术公司 | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 |
MX2012002059A (es) * | 2009-08-20 | 2012-04-19 | Karus Therapeutics Ltd | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. |
CN102020657A (zh) * | 2009-09-11 | 2011-04-20 | 上海艾力斯医药科技有限公司 | 稠合杂芳基衍生物、制备方法及其应用 |
CA2775942A1 (en) | 2009-09-29 | 2011-04-07 | Xcovery Holding Company Llc | Pi3k (delta) selective inhibitors |
CN102762565A (zh) | 2010-02-22 | 2012-10-31 | 弗·哈夫曼-拉罗切有限公司 | 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法 |
UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
WO2012007493A1 (en) | 2010-07-14 | 2012-01-19 | F. Hoffmann-La Roche Ag | Purine compounds selective for ρi3κ p110 delta, and methods of use |
MX2013008822A (es) | 2011-02-09 | 2013-10-07 | Hoffmann La Roche | Compuestos heterociclicos como inhibidores de cinasa fosfatidilinositol-3 (pi3). |
MX2013014151A (es) | 2011-06-03 | 2014-01-23 | Hoffmann La Roche | Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k. |
-
2011
- 2011-12-15 BR BR112013014914A patent/BR112013014914B8/pt active IP Right Grant
- 2011-12-15 MX MX2013006858A patent/MX2013006858A/es unknown
- 2011-12-15 ES ES11808454T patent/ES2530545T3/es active Active
- 2011-12-15 MY MYPI2013701009A patent/MY164910A/en unknown
- 2011-12-15 AR ARP110104706A patent/AR084312A1/es active IP Right Grant
- 2011-12-15 WO PCT/US2011/065101 patent/WO2012082997A1/en active Application Filing
- 2011-12-15 KR KR1020147020819A patent/KR20140099556A/ko not_active Application Discontinuation
- 2011-12-15 US US13/326,524 patent/US8883799B2/en active Active
- 2011-12-15 RS RS20150034A patent/RS53768B1/en unknown
- 2011-12-15 EP EP16151410.4A patent/EP3053925A1/en not_active Withdrawn
- 2011-12-15 NZ NZ609448A patent/NZ609448A/en unknown
- 2011-12-15 SI SI201130343T patent/SI2651951T1/sl unknown
- 2011-12-15 CN CN201180060597.3A patent/CN103313989B/zh active Active
- 2011-12-15 TW TW100146570A patent/TWI441824B/zh active
- 2011-12-15 TW TW103111141A patent/TW201500358A/zh unknown
- 2011-12-15 DK DK11808454.0T patent/DK2651951T3/en active
- 2011-12-15 EA EA201390879A patent/EA026134B1/ru unknown
- 2011-12-15 KR KR1020137018489A patent/KR101548439B1/ko active IP Right Grant
- 2011-12-15 CN CN201610206179.5A patent/CN105859735B/zh active Active
- 2011-12-15 CA CA2820078A patent/CA2820078C/en active Active
- 2011-12-15 UA UAA201308951A patent/UA109688C2/ru unknown
- 2011-12-15 PL PL11808454T patent/PL2651951T3/pl unknown
- 2011-12-15 PT PT118084540T patent/PT2651951E/pt unknown
- 2011-12-15 SG SG10201510347QA patent/SG10201510347QA/en unknown
- 2011-12-15 AU AU2011343712A patent/AU2011343712B2/en active Active
- 2011-12-15 EP EP11808454.0A patent/EP2651951B1/en active Active
- 2011-12-15 EP EP14177962.9A patent/EP2813506B1/en not_active Not-in-force
- 2011-12-15 JP JP2013544769A patent/JP5775171B2/ja active Active
- 2011-12-15 PE PE2013001418A patent/PE20140314A1/es not_active Application Discontinuation
- 2011-12-15 SG SG2013040563A patent/SG190890A1/en unknown
-
2013
- 2013-04-15 IL IL225778A patent/IL225778A/en active IP Right Grant
- 2013-04-19 CL CL2013001093A patent/CL2013001093A1/es unknown
- 2013-04-25 CO CO13105848A patent/CO6710942A2/es unknown
- 2013-05-27 CR CR20130247A patent/CR20130247A/es unknown
- 2013-06-05 ZA ZA2013/04128A patent/ZA201304128B/en unknown
- 2013-06-14 EC ECSP13012692 patent/ECSP13012692A/es unknown
- 2013-11-27 HK HK13113223.7A patent/HK1185871A1/zh unknown
-
2014
- 2014-10-27 US US14/524,204 patent/US9546182B2/en active Active
-
2015
- 2015-02-03 HR HRP20150127AT patent/HRP20150127T1/hr unknown
-
2016
- 2016-12-09 US US15/374,867 patent/US20170233407A1/en not_active Abandoned
-
2019
- 2019-07-10 US US16/507,523 patent/US20190330235A1/en not_active Abandoned
-
2021
- 2021-05-05 AR ARP210101230A patent/AR122019A2/es unknown
- 2021-11-24 US US17/535,124 patent/US20220348593A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY164910A (en) | Tricyclic pi3k inhibitor compounds and methods of use | |
MX2014005289A (es) | Compuestos de piperazina alquilados. | |
MA32272B1 (fr) | Inhibiteurs de raf de pyrazole [3,4-b]pyridine | |
EA201290957A1 (ru) | Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения | |
MX340013B (es) | Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso. | |
TR201909849T4 (tr) | Btk etkinliği inhibitörleri olarak heteroaril piridon ve aza-piridon bileşikleri. | |
MX2014001239A (es) | Compuestos de pirazolo [3,4-c] piridina y metodos de uso. | |
MX2014005282A (es) | Compuestos de 8-fluoroftalazin-1 (2h) -ona. | |
MX2014005285A (es) | Compuestos biciclicos de piperazina. | |
MX2014014828A (es) | Compuestos de 5-azaindazol y metodos de uso. | |
MX2011009167A (es) | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas. | |
MX2011012520A (es) | Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos. | |
MY160349A (en) | Pyridone and aza-pyridone compounds and methods of use | |
PH12013501779B1 (en) | Pyrrolopyridines as kinase inhibitors | |
PH12015500488A1 (en) | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
TW200942536A (en) | PIM kinase inhibitors and methods of their use | |
BR112013020329A2 (pt) | compostos heterocíclicos como inibidores da pi3-quinase | |
SG10201407781SA (en) | Benzoxepin PI3K Inhibitor Compounds And Methods Of Use | |
MX2010002543A (es) | Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso. | |
SG178899A1 (en) | Raf inhibitor compounds and methods of use thereof | |
BR112012019635A2 (pt) | compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso | |
MX361157B (es) | Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso. | |
ECSP10010510A (es) | Compuestos del inhibidor de raf y métodos de uso de los mismos | |
SG178900A1 (en) | Raf inhibitor compounds and methods of use thereof | |
CY1116014T1 (el) | Τρικυκλικες ενωσεις αναστολεα της ρι3κ και μεθοδοι χρησης |